A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis

PHASE2CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

August 2, 2022

Primary Completion Date

May 13, 2025

Study Completion Date

May 13, 2025

Conditions
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Interventions
DRUG

NNC6019-0001

Participants will receive i.v infusionof NNC6019-0001.

DRUG

Placebo (NNC6019-0001)

Participants will receive i.v. infusion of placebo (NNC6019-0001).

Trial Locations (34)

12808

II. interni klinika VFN - Kardiologie a angiologie, Prague

21201

Univ of MD Schl of Med, Baltimore

University of Maryland School of Medicine, Baltimore

27100

Centro per lo Studio e la Cura delle Amiloidosi Sistemiche Fondazione IRCCS Policlinico San Matteo, Pavia

28222

Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda

Hospital Universitario Puerta de Hierro Majadahonda, Madrid

31059

Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil-1, Toulouse

Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil-1, Toulouse Cedex 9 TSA 50032

32224

Mayo Clinic Jacksonville, Jacksonville

48149

Universitätsklinikum Münster - Klinik für Kardiologie I, Münster

55905

Mayo Clinic Rochester, Rochester

56124

Fondazione CNR-Regione Toscana Gabriele Monasterio, Pisa

60208

NW Univ-Bluhm Cardiovasc Inst, Evanston

69120

UniklinikHeidelberg - Innere Med. III - Kardiologie, Angiologie, Pneumologie, Heidelberg

81377

LMU Klinikum München Klinik und Poliklinik 1, München

85054

Mayo Clinic Arizona, Phoenix

90211

Cedars-Sinai Medical Center_Los Angeles, Beverly Hills

94000

Ap-Hp-Hopital Henri Mondor, Créteil

94305

Stanford Hlth Cre-Boswell Clin, Stanford

97078

Universitatsklinikum Wurzburg AöR, Würzburg

Universitatsklinikum Würzburg - Zentrum für Herzinsuffizienz, Würzburg

97239-4501

Oregon Hlth Sci Univ-Portland, Portland

T2N 4Z6

University of Calgary_Cardiology, Calgary

V5Z 1M9

Ctr for Cardiovascular Innovation, Vancouver

807-8556

Hospital of the University of Occupational and Environmental Health, Cardiology, Nephrology, Fukuoka

734-8551

Hiroshima University hospital, Cardiovascular Medicine, Hiroshima

860-8556

Kumamoto University Hospital, Cardiovascular Medicine, Kumamoto-shi, Kumamoto

390-8621

Shinshu University Hospital, Department of Neurology, Nagano

852-8501

Nagasaki University Hospital, Cardiovascular Medicine, Nagasaki

700-8558

Okayama University Hospital_Cardiovascular Medicine, Okayama-shi, Okayama

9713 GZ

UMC Groningen, Groningen

3584 CX

Universitair Medisch Centrum Utrecht, Utrecht

4835-044

Hospital da Senhora da Oliveira - Guimarães, Guimarães

Unidade Local de Saude do Alto Ave, E.P.E., Guimarães

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT05442047 - A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis | Biotech Hunter | Biotech Hunter